Dear Pharmacist,

Optinose is pleased to announce the availability of XHANCE™ (fluticasone propionate) nasal spray 93 mcg. XHANCE uses an exhalation delivery system (EDS) that is designed to deliver medication high and deep in the nasal passages, where nasal polyps originate and sinuses drain and ventilate. Product details are listed below.

**XHANCE nasal spray is indicated for the treatment of nasal polyps in patients 18 years of age or older.**

**PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>NDC</th>
<th>UPC</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>71143-375-01</td>
<td>3 71143 37501 1</td>
<td>1 spray per nostril twice daily: 1 unit = 30 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 sprays per nostril twice daily: 2 units = 30 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength</th>
<th>Fill Volume</th>
<th>Wholesale Acquisition Cost (WAC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>93 mcg; one unit provides 120 metered sprays</td>
<td>16 mL</td>
<td>$446.25</td>
</tr>
</tbody>
</table>

This product is not bioequivalent to Flonase®

Thank you for making XHANCE readily available to your physicians and their patients during this product introduction. If you have any questions about XHANCE, feel free to contact our Customer Service department at 833-678-6673.

Sincerely,
The Optinose team

Please see Important Safety Information on the reverse side.
Please see full Prescribing Information at www.xhance.com.
IMPORTANT SAFETY INFORMATION for XHANCE (fluticasone propionate) nasal spray, 93 mcg

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, *Candida albicans* infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.

- Close monitoring for glaucoma and cataracts is warranted.

- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.

- Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.

- Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.

- Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:
The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

INDICATIONS AND USAGE:
XHANCE nasal spray is indicated for the treatment of nasal polyps in patients 18 years of age or older.

Please see full Prescribing Information at www.xhance.com.